Ectopia

ITC Rules Apple Violated AliveCor's Patents

Retrieved on: 
Friday, December 23, 2022
Administrative law judge, Atrial fibrillation, SOC, United States International Trade Commission, Cardiac cycle, Wireless ambulatory ECG, Apple Watch, Patient, Arrhythmia, ECG, Apple Watch Series 4, Intellectual property, PTAB, Alivecor, ALJ, Patent, Stroke, HIPAA, Risk, FDA, Deep learning, Multimedia, ITC, LEO, Administrative law, Goliath, Sale, Certification, Patent Trial and Appeal Board, Ectopia, ISO, Generic drug, Medical device, Bradycardia, Apple, Tachycardia

MOUNTAIN VIEW, Calif., Dec. 22, 2022 /PRNewswire/ -- AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that the International Trade Commission (ITC) has issued its Final Determination ruling that Apple Watch infringed AliveCor's patented technology. The ITC issued a Limited Exclusion Order (LEO), a cease and desist order and set a bond in the amount of $2.00 per unit of infringing Apple Watches imported or sold during the Presidential review period, potentially impacting sales of millions of infringing Apple Watches.

Key Points: 
  • The ITC issued a Limited Exclusion Order (LEO), a cease and desist order and set a bond in the amount of $2.00 per unit of infringing Apple Watches imported or sold during the Presidential review period, potentially impacting sales of millions of infringing Apple Watches.
  • The ITC has suspended enforcement of its orders pending resolution of AliveCor's appeal of the U.S. Patent and Trademark Office, Patent Trial and Appeal Board's ("PTAB") decision finding the asserted patents unpatentable.
  • Today's ruling marks a victory for AliveCor and affirms the Initial Determination issued in June by Administrative Law Judge (ALJ) Cameron Elliot of the ITC.
  • In addition to fighting Apple on patent infringement in the ITC, AliveCor continues to seek relief in the Northern District of California from Apple's anticompetitive behavior.

AliveCor's KardiaMobile Card Honored by the 2022 Fierce Life Sciences Innovation Awards and the 2023 CES® Innovation Awards

Retrieved on: 
Thursday, November 17, 2022
Alivecor, HIPAA, Atrial fibrillation, CTA, Arrhythmia, Certification, Deep learning, Senior, FDA, Consumer Technology Association, ISO, Sale, Multimedia, Patient, ECG, SOC, Stroke, The Economist, Cardiac cycle, Engineering, Global marketing, Digital health, Ectopia, Medical device, Bradycardia, Tachycardia

MOUNTAIN VIEW, Calif., Nov. 17, 2022 /PRNewswire/ -- AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced that KardiaMobile Card, the world's first credit-card-sized, FDA-cleared personal ECG device, has been named a 2022 Fierce Life Sciences Innovation Awards winner in the Medical Device Innovation category and a CES® 2023 Innovation Awards Honoree in the Digital Health category.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 17, 2022 /PRNewswire/ -- A liveCor , theleading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced that KardiaMobile Card, the world's first credit-card-sized, FDA-cleared personal ECG device, has been named a 2022 Fierce Life Sciences Innovation Awards winner in the Medical Device Innovation category and a CES 2023 Innovation Awards Honoree in the Digital Health category.
  • Introduced earlier this year, KardiaMobile Card is engineered to provide class-leading performance in the world's thinnest, lightest personal ECG.
  • The KardiaMobile Card is designed with convenience and durability in mind, helping patients manage their cardiac health anytime, anywhere.
  • The annual Fierce Life Sciences Innovation Awards, organized by Fierce Biotech and Fierce Pharma, identifies and highlights the latest and most impactful innovations in the life sciences industry across six categories.

BIOTRONIK Announces Collaboration with AliveCor As First In A Series of Strategic Partnerships to Disrupt Cardiac Digital Health With AI-Enabled Solutions

Retrieved on: 
Thursday, September 8, 2022
ISO, Partnership, ECG, Ectopia, Technology, Caregiver, Arrhythmia, AF2, Ohio State University Wexner Medical Center, Global Sales Law Project, Solution, AF, Decision-making, HIPAA, Sale, Heart, Incidence, EHR, Physician, Kannel, Diagnosis, Prognosis, Data management, SOC, Workflow, Deep learning, Health, FACC, Medicine, Stroke, FDA, Certification, Atrial fibrillation, Digital health, Cardiac cycle, Human body, Longevity, Patient, Medical device, Alivecor, FHRS, Bradycardia, Tachycardia, MD

LAKE OSWEGO, Ore., Sept. 8, 2022 /PRNewswire/ -- BIOTRONIK announced today its partnership with AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services. This partnership will combine the strengths of BIOTRONIK's BIOMONITOR Injectable Cardiac Monitor (designed with industry-leading 95.1% p-wave visibility1 across all cardiac cycles and 5.5 year longevity) with AliveCor's AI-enabled, clinically validated, medical-grade KardiaMobile 6L and KardiaMobile Card ECG technology. Through this pilot collaboration, healthcare providers will be able to access clinically relevant heart rhythm analyses and actionable reports to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and assess means to drive improvements to patient care and clinical outcomes.

Key Points: 
  • Up to 25% of stroke patients present with AF2, the most common type of treated cardiac arrhythmia.
  • Pairing AliveCor's KardiaMobile ECGs with BIOTRONIK's implantable device data strives to streamline workflow by providing comprehensive visibility within a single solution.
  • "Connecting wearable and implantable cardiac diagnostic device data from the earliest stages in the care continuum is groundbreaking," said Kenneth Nelson, Head of Digital Health and Diagnostics at BIOTRONIK.
  • This pilot collaboration is the first in a series of partnerships with leading digital health organizations to improve the delivery of connected care in cardiac diagnostics and remote patient monitoring.

AliveCor Announces Series F Financing to Help Expand Offerings to Key Healthcare Industry Stakeholders

Retrieved on: 
Tuesday, August 16, 2022
FDA, Multimedia, CVC, Risk, Health care, Atrial fibrillation, CEO, Qualcomm Ventures, Technology, Growth, Sale, ECG, Director, GE Healthcare, Board, Patient, Stroke, Ectopia, Certification, Khosla Ventures, Partnership, Cardiology, Deep learning, SOC, HIPAA, Privacy, Physician, Arrhythmia, ISO, Cardiac cycle, Hospital, Medical device, Tachycardia, Alivecor, Bradycardia

MOUNTAIN VIEW, Calif., Aug. 16, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced its Series F Financing led by GE Healthcare.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 16, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced its Series F Financing led by GE Healthcare.
  • These subscription services are supported by the company's personal ECG devices, including KardiaMobile, KardiaMobile 6L, and KardiaMobile Card.
  • This financing will also allow for continued advancements in AliveCor's AI roadmap and pipeline of innovations.
  • "This financing will help accelerate our growth into new strategic sectors and markets, enabling us to connect even more people to life-saving remote heart care."

ITC Administrative Law Judge Finds Apple Infringed AliveCor's Patented Technology

Retrieved on: 
Tuesday, June 28, 2022
FDA, Atrial fibrillation, Deep learning, Patient, Apple Watch, CEO, United States International Trade Commission, Sale, Alivecor, Stroke, HIPAA, Ectopia, ITC, ISO, Technology, ECG, SOC, Certification, Cardiac cycle, Arrhythmia, ALJ, Multimedia, Joint, Administrative law judge, Mobile phone, Medical device, Tachycardia, Bradycardia, Apple

MOUNTAIN VIEW, Calif., June 27, 2022 /PRNewswire/ -- AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that Administrative Law Judge (ALJ) Cameron Elliot of the International Trade Commission (ITC) issued an Initial Determination finding that Apple infringed AliveCor's patented technology. If affirmed by the full ITC, the ALJ's finding of a violation could lead to the issuance of a limited exclusion order barring the import of infringing Apple Watches into the United States.

Key Points: 
  • MOUNTAIN VIEW, Calif., June 27, 2022 /PRNewswire/ -- AliveCor , the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that Administrative Law Judge (ALJ) Cameron Elliot of the International Trade Commission (ITC) issued an Initial Determination finding that Apple infringed AliveCor's patented technology.
  • If affirmed by the full ITC, the ALJ's finding of a violation could lead to the issuance of a limited exclusion order barring the import of infringing Apple Watches into the United States.
  • AliveCor filed its complaint with the ITC in April 2021 alleging that Apple infringed AliveCor's patented technology, and filed an anticompetition complaint against Apple in May 2021 .
  • The ITC is currently scheduled to issue a Final Determination by October 26, 2022.

AliveCor Launches KardiaComplete to Help Reduce the Rising Health and Economic Costs of Heart Disease

Retrieved on: 
Tuesday, May 3, 2022
Atrial fibrillation, Deep learning, Plague Inc: Evolved, Health, Coronary artery disease, Stroke, Heart failure, Physician, Patient, Arrhythmia, Heart, FDA, HIPAA, Compliance, Ectopia, MD, Movement, Sale, Disease, ECG, Education, Cardiac cycle, Omron, Technology, HIV disease progression rates, Hypertension, Risk, Medical device, Medical imaging, Pharmaceutical industry, Bradycardia, Alivecor, Tachycardia

MOUNTAIN VIEW, Calif., May 3, 2022 /PRNewswire/ -- AliveCor, the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the launch of KardiaComplete, a comprehensive heart health enterprise solution designed to drive improved health outcomes and reduce the cost of cardiac care. The service will be available to people diagnosed with hypertension and arrhythmias, like atrial fibrillation, through their self-insured employers, health insurance plans and health systems.

Key Points: 
  • The service will be available to people diagnosed with hypertension and arrhythmias, like atrial fibrillation, through their self-insured employers, health insurance plans and health systems.
  • KardiaComplete also offers support from a virtual assistant and personalized analyses of heart data to empower people living with heart conditions to better manage their health.
  • AliveCor plans to expand its future KardiaComplete offerings to people living with other serious heart conditions, such as heart failure and coronary artery disease.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

GE Healthcare, AliveCor Partnership Aims to Increase Convenience for Patients and Help Reduce Cardiac-Related Hospitalizations by Improving the Quality and Integration of Patient Data

Retrieved on: 
Wednesday, March 16, 2022
Software, Biotechnology, Practice Management, Pharmaceutical, Health, Medical Devices, Data Management, Technology, MUSE, Twitter, 6L, Intelligence, Patient, News, PMID, Partnership, Hospital, IPED, FDA, Multimedia, Risk, Atrial fibrillation, Attention, Cardiac cycle, Compliance, Emergency department, Â, Insight, Environment, Deep learning, GE Healthcare, Stroke, Algorithm, Wireless ambulatory ECG, ECG, Sale, PDF, Palpitations, EMR, HIMSS, Communication, Privacy, CEO, Instagram, Thomas Edison, Death, NYSE, Arrhythmia, Physician, HIPAA, Health, Ectopia, Efficiency, Workflow, Ecosystem, LinkedIn, Medical imaging, Medical device, Pharmaceutical industry, Tachycardia, Facebook, Bradycardia, Alivecor, GE Healthcare, AliveCor, GE HEALTHCARE, ALIVECOR

View the full release here: https://www.businesswire.com/news/home/20220316005427/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220316005427/en/
    Atrial fibrillation, the most common type of treated heart arrhythmia, is associated with a highly elevated risk of stroke.
  • Currently, if the patient chooses to share the remote ECG, a physician sees AliveCor six-lead ECGs on a patients phone in an office visit or a PDF emailed by the patient.
  • GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE).
  • AliveCor protects its customers with stringent data security and compliance practices , achieving HIPAA compliance and SOC2 Type 1 and Type 2 attestations.

TLV recommends AliveCor's smartphone-based ECG as a more cost-effective option for the detection of atrial fibrillation compared to Holter ECG

Retrieved on: 
Tuesday, February 22, 2022
Swedish Dental and Pharmaceutical Benefits Agency, National Health Service, ECG, Compliance, Atrial fibrillation, Time, Ectopia, Efficiency, MTP, Smartphone, Diagnosis, Arrhythmia, Deep learning, AF, NICE, Alivecor, Wireless ambulatory ECG, Sale, Stroke, Business, Dental, Electrode, Finger, HIPAA, TLV, FDA, Cardiac cycle, Patient, Technology, National Institute for Health and Care Excellence, NHS, Cardiovascular disease, Standard of care, National Institute, Software, Medical device, Pharmaceutical industry, Bradycardia, Kardia, Tachycardia

KardiaMobile is used together with the KardiaApp application for patients and the KardiaPro software for healthcare professionals.1

Key Points: 
  • KardiaMobile is used together with the KardiaApp application for patients and the KardiaPro software for healthcare professionals.1
    KardiaMobile and KardiaPro were compared to the 'usually used' Holter ECG.
  • The scenario analysis in the health economic evaluation concluded that the use of KardiaMobile and KardiaPro can provide greater benefit at a lower cost.
  • Even if no stroke is avoided, using KardiaMobile saves costs compared to Holter ECG 24-hours.1
    AF is the most common arrhythmia in adults.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

AliveCor Appoints Patricia Baran to Serve as Senior Vice President, Healthcare Americas

Retrieved on: 
Thursday, February 10, 2022
Chronic care management, Senior, Cardiac cycle, Pharmacy, Multimedia, Ectopia, Teladoc Health, Solution, ReachOut Healthcare America, Leadership, Cardinal Health, Sale, FDA, Technology, Health system, Patient, Deep learning, Employment, ECG, Wage and Hour Division, Compliance, Arrhythmia, Atrial fibrillation, Health, Hospital, GE Healthcare, Stroke, Alivecor, Patty Stonesifer, HIPAA, Medicine, Medical device, Bradycardia, Tachycardia

MOUNTAIN VIEW, Calif., Feb. 10, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Patricia Baran as Senior Vice President, Healthcare Americas.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 10, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Patricia Baran as Senior Vice President, Healthcare Americas.
  • In this role, Baran will report to Vincent Balsamo , Executive Vice President of Worldwide Sales.
  • Baran will lead the Employer, Payor, and Health System business segments supporting AliveCor's clients and their members with a complete cardiac care management solution.
  • She started her career as a registered nurse and remains a dedicated and passionate advocate for transforming healthcare.

FDA Clears World's First Credit-Card-Sized Personal ECG

Retrieved on: 
Tuesday, February 1, 2022
Hypertension, CEO, Emergency medicine, ECG, Patient, HIPAA, Sale, Water, Atrial fibrillation, Arrhythmia, Systematic review, Face, Stroke, Cardiac cycle, Technology, COVID-19, Alivecor, Deep learning, INT, Public health, Cardiovascular disease, Wireless ambulatory ECG, Compliance, Blood pressure, Smartphone, American Heart Association, Weather, Ectopia, FDA, Ventricular tachycardia, Multimedia, Caregiver, Medical device, Pharmaceutical industry, MD, Bradycardia, Tachycardia, Kardia

MOUNTAIN VIEW, Calif., Feb. 1, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the launch of KardiaMobile Card, the slimmest, most convenient personal ECG device ever created.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 1, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the launch of KardiaMobile Card, the slimmest, most convenient personal ECG device ever created.
  • KardiaMobile Card makes history as the world's first credit-card-sized ECG ever cleared by the FDA.
  • "After disrupting traditional ECG monitoring with our game-changing Kardia platform, we have now achieved the unprecedented milestone of creating the first-ever credit-card-sized personal ECG," said Priya Abani, CEO of AliveCor.
  • KardiaMobile Card pairs with a smartphone using Bluetooth technology to detect six of the most common arrhythmias, more than any other personal ECG on the market.